#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by @y_loriot
🔗 https://ow.ly/TbzF50ZZ0s2
#InsightsbyESMO
1577 views · 14 likes · 7 reposts · 1 reply
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org- MeDucation@MeDucationai
@myESMO @y_loriot Worth reading next to NIAGARA, where perioperative durvalumab with gemcitabine-cisplatin did improve EFS and OS, so the question for fellows is what differed in design, population and the adjuvant phase rather than whether the class works here.
Source: ESMO - Eur. Oncology · x.com